Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Annovis Bio ( (ANVS) ) just unveiled an announcement.
On February 5, 2025, Annovis Bio Inc. announced the commencement of its pivotal Phase 3 study for the drug buntanetap in early Alzheimer’s disease, marking a significant step toward market approval. The study, which follows promising results from previous trials, is designed to assess both symptomatic and potential disease-modifying effects over an 18-month period and involves over 750 participants across the United States.
More about Annovis Bio
Annovis Bio Inc., headquartered in Malvern, Pennsylvania, is a late-stage clinical drug platform company focused on pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease.
YTD Price Performance: -38.55%
Average Trading Volume: 411,788
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $44.7M
For an in-depth examination of ANVS stock, go to TipRanks’ Stock Analysis page.